Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
|Articles|February 2, 2022
Best practices for treating MASKNE in children and adolescents
Author(s)Lois Levine, MA
How to prevent, minimize, and treat maskne
Advertisement
Contemporary Pediatrics® recently spoke with Alanna F. Bree, MD, a board-certified pediatric dermatologist and clinical assistant professor of Dermatology at Baylor College of Medicine and Texas Children’s Hospital in Houston, Texas, as well as a Society of Pediatric Dermatology member, about maskne, including how long it has been around (since before the pandemic); how maskne presents differently in young children compared to teenagers; and how to best treat and prevent.
Advertisement
Related to this article
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
Infant skin care: Choosing products that protect the skin barrier
3
Mirikizumab meets 1-year remission end point in pediatric UC
4
Testosterone changes linked to emotional distress in pubertal girls
5